Back to top

Genentech announces Krascendo 1 study met primary, key secondary endpoint

Genentech, a member of Roche (RHHBY), announced results from the Phase III Krascendo 1 study evaluating divarasib, an investigational next-generati...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Roche Holding AG (RHHBY)

Rogers Corporation (ROG)

Roper Technologies, Inc. (ROP)